You are here

  • Home
  • Archive
  • Volume 11, Issue Suppl 1
  • 638 Characterisation of the immune response to EO2401, a new immunotherapy approach against cancer, plus nivolumab in recurrent glioblastoma: The EOGBM1–18/ROSALIE study

Article metrics

Article menu

Download PDFPDF

Regular and Young Investigator Award Abstracts
Clinical Trial In Progress
638 Characterisation of the immune response to EO2401, a new immunotherapy approach against cancer, plus nivolumab in recurrent glioblastoma: The EOGBM1–18/ROSALIE study

 

Online download statistics by month:

Online download statistics by month: November 2023 to June 2025

AbstractFullPdf
Nov 2023148013
Dec 20233803
Jan 20245102
Feb 20243801
Mar 20242803
Apr 20243203
May 20243800
Jun 20241600
Jul 20242003
Aug 20241602
Sep 20242602
Oct 20242802
Nov 20243202
Dec 20242805
Jan 20252409
Feb 2025502
Mar 2025002
Apr 2025006
May 2025103
Jun 2025104
Total570067